- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07835113
Tissue Sensor for Semirigid Thulium Fiber Laser Ureterolithotripsy (Tissue Sensor)
Tissue Sensor to Reduce Laser-Induced Ureteral Injury During Semirigid Thulium Fiber Laser Ureterolithotripsy: The TISSUE Multicenter Randomized Controlled Trial
Tissue Sensor (TS) is a technology designed to automatically deactivate laser emission when contact between the laser fiber and tissue is detected. It is hypothesized that the use of TS during contact laser ureterolithotripsy may reduce unintended laser exposure of the ureteral mucosa, thereby decreasing the risk of immediate thermal injury to the ureteral wall and subsequent scar-related narrowing.
To reduce the influence of baseline risk factors for stricture, the study will enroll a homogeneous population of patients without urinary tract anomalies, previous surgery on the study ureter, or impacted stones. The procedure will be performed according to a standardized protocol using a semirigid ureteroscope, a thulium fiber laser, and predefined technical restrictions. The study is limited to patients with stones in the mid or distal ureter. This approach is intended to minimize the likelihood of stone retropulsion into the kidney, standardize the surgical technique, reduce the need for conversion to flexible ureteroscopy, and maximize comparability between the study groups.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nikita Astakhov
- Numéro de téléphone: +8 (968) 490-46-72
- E-mail: astakhov.nikita@inbox.ru
Sauvegarde des contacts de l'étude
- Nom: Vigen Malkhasyan, Doctor of Medical Sciences
- Numéro de téléphone: +79096441688
- E-mail: botkinhospital@zdrav.mos.ru
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
• Age 18 years or older.
- A single stone in the mid or distal ureter.
- Maximum stone diameter of 15 mm or less on preoperative CT.
- An indication for elective semirigid laser ureterolithotripsy.
- Feasibility of performing the procedure with a semirigid ureteroscope.
- No active urinary tract infection at the time of the intervention.
- Ability to undergo CT follow-up and complete 12 months of follow-up.
- Signed written informed consent.
Exclusion Criteria:
-
• Age 18 years or older.
- A single stone in the mid or distal ureter.
- Maximum stone diameter of 15 mm or less on preoperative CT.
- An indication for elective semirigid laser ureterolithotripsy.
- Feasibility of performing the procedure with a semirigid ureteroscope.
- No active urinary tract infection at the time of the intervention.
- Ability to undergo CT follow-up and complete 12 months of follow-up.
- Signed written informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Patients after ureterolithotrypsy with Tissue Sensor activated
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor activated. All automatic system trigger events will be recorded by the laser system or in the study case report form and, whenever possible, synchronized with the procedure video recording |
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor activated. All automatic system trigger events will be recorded by the laser system or in the study case report form and, whenever possible, synchronized with the procedure video recording |
|
Expérimental: Patients after ureterolithotrypsy with Tissue Sensor deactivated
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the ureteral mucosa will be recorded from the procedure video |
Semirigid TFL ureterolithotripsy will be performed with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the ureteral mucosa will be recorded from the procedure video. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of intraoperative laser-induced injury to the ureteral mucosa
Délai: intraoperative
|
Incidence of intraoperative laser-induced injury to the ureteral mucosa, defined as any visible injury compatible with exposure to an activated laser fiber, as determined by independent blinded video assessment. |
intraoperative
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of postoperative ureteral stricture
Délai: 12 months.
|
Incidence of postoperative ureteral stricture detected during the 12 months after the intervention.
|
12 months.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MoscowBotkinHospital2
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .